The Latest Breaking News from CELC

Celcuity Q1 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer. On the company

MarketBeat · May 14

3 Stocks You’ll Wish You Bought Before 2026

These three up-and-coming stocks are delivering massive 2025 gains and may have more room to run as key catalysts unfold

MarketBeat · Dec 3, 2025

Up 215% YTD, Should You Grab This Growth Stock Before It’s Too Late?

If successful, Celcuity could emerge as one of the breakout biotech stars of 2025.

Barchart · Jul 29, 2025

Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022

Celcuity Inc (NASDAQ:CELC) concluded two formal meetings with the FDA to obtain their feedback on the gedatolisib Phase 3 trial in the breast cancer setting. The study dubbed VIKTORIA-1 will evaluate gedatolisib combined with fulvestrant with or without palbociclib in HR+/HER2- advanced breast cancer. The trial will include adult patients whose disease has…

Benzinga · Mar 24, 2022

Recap: Celcuity Q4 Earnings

Celcuity (NASDAQ:CELC) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Celcuity beat estimated earnings by 2.63%, reporting an EPS of $-0.37 versus an estimate of $-0.38.

Benzinga · Mar 23, 2022

Preview: Celcuity's Earnings

Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that Celcuity will report an earnings per share (EPS) of $-0.38.

Benzinga · Mar 22, 2022

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity

The 

Benzinga · Jan 18, 2022